KYNB Kyntra Bio, Inc.

NASDAQ

$6.94

Kyntra Bio, Inc. (KYNB) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $3.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.3% since its last earnings release on August 13, 2026.

Kyntra Bio Missed Consensus Estimates

Thursday, August 13, 2026 · 4:02 PM ET

3rd Quarter, Sep 2026

Thursday · 4:00 PM ET

Earnings Whisper

-

vs ($3.66)

Rev est $1.97M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $7.62

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kyntra Bio, Inc.

Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.